SERB Pharmaceuticals

What SERB Pharmaceuticals does

SERB Pharmaceuticals is a global specialty pharmaceutical company headquartered in Luxembourg with origins dating to 1951 in Paris (as Société d'Études et de Recherches Biologiques). Following Charterhouse Capital Partners' acquisition of a majority stake in September 2017, with co-sponsorship from Partners Group and Merieux Equity Partners, the company executed a series of transformative acquisitions — Veriton Pharma (2020), BTG Specialty Pharmaceuticals (2021), Xermelo ex-US/Japan rights from Ipsen (2022), Vistogard and Xuriden from Wellstat (2023), RSDL from Emergent BioSolutions (2024), Aurlumyn from CiVi Biopharma (2024), and Y-mAbs Therapeutics (2025) — building a portfolio of 70+ medicines focused on three franchises: rare diseases (oncology, neurology, metabolic), emergency and critical care, and CBRN medical countermeasures. The company operates a hybrid manufacturing model anchored by a proprietary polyclonal antibody manufacturing platform (one of the few globally capable of commercial-scale production with 20+ years of process know-how and two FDA-approved products) combined with in-house facilities in Wales, Australia, Utah, and Mississippi, supplemented by European contract manufacturers.

SERB generates revenue primarily through direct sales of its specialty pharmaceutical products to hospitals, healthcare systems, first responders, and emergency preparedness agencies in 18 countries across the US, Europe, and the Middle East, with a distribution partner network extending reach to 80–100+ countries. Secondary revenue mechanics include licensing and acquisition-integration economics (e.g., the €115M Idefirix licensing deal with Hansa Biopharma), government and military procurement for CBRN products such as RSDL and potassium iodide, specialty pharmacy channels in the US (BioMatrix, Cardinal Health), and direct-to-consumer e-commerce for ThyroSafe. GTM motion combines enterprise field sales, regulatory and KOL engagement, patient association partnerships, and 24/7 medical information services. The company is structured under SERB S.à.r.l. (Luxembourg) as the parent holding entity, with operating subsidiaries including BTG International (US), Protherics UK Ltd, Veriton Pharma, Y-mAbs Therapeutics, and SERB GmbH / SERB SAS / SERB Sp. z.o.o. / SERB S.A. as regional market entities across Europe.

Name

SERB Pharmaceuticals

Legal name

SERB S.à.r.l.

Website

https://serb.com

Company type

Private

Founded year

1951

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SERB Pharmaceuticals is a global specialty pharmaceutical company supplying 70+ medicines for rare diseases, emergency care, and CBRN medical countermeasures to healthcare providers, governments, and first responders across 100+ countries through direct sales in 18 markets and a distribution partner network.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Specialty pharmaceuticals
• Emergency care medicines
• Rare disease treatments
• Medical countermeasures
• Antidote manufacturing

Headquarters

HQ city

Luxembourg

HQ country

Luxembourg

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Specialty Pharmaceutical Product Sales: SERB generates revenue through the sale of its portfolio of 70+ specialty pharmaceutical products covering rare diseases, rare emergency medicine, and medical countermeasures. Products are sold through direct sales teams in the US, Europe, and Middle East, and through distribution partners in 80+ countries worldwide.
2. Licensing and Acquisition Integration: SERB grows through acquiring or licensing products (e.g., Idefirix licensing from Hansa Biopharma for €115M, Y-mAbs acquisition for ~$412M) and commercialising them through its integrated platform, generating revenue from product sales in new geographies.
3. Medical Countermeasure Supply: Supply of antidotes and medical countermeasures (CBRN) to hospitals, healthcare systems, first responders, emergency preparedness agencies, and non-profit organisations, often through government procurement contracts.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

SERB Pharmaceuticals is a global specialty pharmaceutical company that develops, manufactures, and commercialises a portfolio of 70+ medicines focused on emergency care, rare diseases, and medical countermeasures (including CBRN preparedness). The company acquires, licenses, or in-licenses niche products from larger pharmaceutical companies and integrates them into its commercial platform, selling directly in 18 countries (US, Europe, Middle East) and through distribution partners in 80+ additional countries. Core product categories include antidotes, antivenoms, opioid overdose reversal agents, thyroid blocking agents, rare oncology, rare neurology, and rare metabolic disease therapies.

Product overview

SERB Pharmaceuticals is a global specialty pharmaceutical company offering a diversified portfolio of over 70 essential medicines across critical care, rare diseases, and medical countermeasures. The company operates as a platform of specialized products rather than a unified software product. The portfolio includes antidotes (Voraxaze®, DigiFab®, CroFab®, Cyanokit®, Fomepizole), emergency medicines (Aurlumyn™, RSDL®, Narcan®, ThyroSafe®), rare disease treatments (Danyelza®, Xermelo®, Vistogard®, Xuriden®, Firdapse®), and neurological therapies (Epistatus®, Mysoline®, Xenazine®). The company serves healthcare providers in over 100 countries through direct sales in 18 countries, leveraging a fully integrated pharmaceutical platform covering acquisition, development, manufacturing, launch, and commercialization of specialist medicines.

Differentiator

Problem solved

Functional benefit

Products and services

• Voraxaze (glucarpidase) Glucarpidase 1000 units/vial powder for solution for injection; an antidote for rescue therapy in high-dose methotrexate toxicity, reducing toxic plasma methotrexate concentrations in patients with delayed elimination. Indicated for adults and children with delayed methotrexate elimination or at risk of methotrexate toxicity.
• Danyelza (naxitamab-gqgk) Naxitamab-gqgk 40mg/10ml for oncology treatment, indicated in combination with GM-CSF for relapsed or refractory high-risk neuroblastoma in bone or bone marrow. Acquired through the Y-mAbs Therapeutics acquisition.
• Cyanokit (hydroxocobalamin) Hydroxocobalamin 5g powder for solution for infusion; an antidote for cyanide poisoning treatment.
• DigiFab (digoxin immune Fab) Digoxin immune Fab (ovine) 40 mg/vial lyophilized powder for solution for intravenous injection; antidote for life-threatening digitalis intoxication. First received European regulatory approval (Swissmedic) in 2010.
• CroFab (Crotalidae Polyvalent Immune Fab) Crotalidae Polyvalent Immune Fab (Ovine) 1gr/vial lyophilized powder for solution for intravenous injection; antivenom for pit viper envenomation.
• Aurlumyn (iloprost IV) Iloprost injection for intravenous use; a vasodilator and platelet aggregation inhibitor, the only FDA-approved treatment for severe frostbite to reduce the risk of digit amputations.
• RSDL (Reactive Skin Decontamination Lotion) Medical device with DAM and KBDO pre-impregnated foam sponge applicator pad for skin decontamination; FDA-cleared device to remove or neutralize chemical warfare agents from the skin in one step.
• Vistogard (uridine triacetate) Uridine triacetate 10g oral granules; emergency treatment for adult and pediatric patients following fluorouracil or capecitabine overdose.
• Xuriden (uridine triacetate) Uridine triacetate 2g; treatment for hereditary orotic aciduria (HOA) in adult and pediatric patients.
• Xermelo (telotristat ethyl) Telotristat ethyl 250 mg; treatment for carcinoid syndrome diarrhoea in combination with somatostatin analogue therapy in adults inadequately controlled by SSA therapy.
• ThyroSafe (Potassium Iodide Tablets) Potassium iodide tablets USP 130mg; thyroid blocking medicine for use in nuclear radiation emergencies to protect the thyroid gland from radioactive iodine uptake. Also available as Kaliumjodid SERB 65mg in Germany.
• Epistatus (midazolam oromucosal solution) Midazolam 2.5mg, 5mg, 7.5mg or 10mg oromucosal solution pre-filled syringe; anticonvulsant for treatment of prolonged acute convulsive seizures in children and adolescents aged 10 to less than 18 years.
• Firdapse (amifampridine) Amifampridine 10mg; treatment for rare neurological conditions (Lambert-Eaton myasthenic syndrome). Licensed from BioMarin for Europe in 2019.
• Radiogardase (Prussian blue) Prussian blue 500mg capsules; antidote for internal contamination with radioactive cesium and thallium. Licensed from Heyl Pharmaceuticals in 2013.
• Fomepizole SERB Fomepizole 5mg/ml concentrate for solution for infusion; antidote for ethylene glycol and methanol poisoning.
• Narcan (naloxone) Naloxone 0.4mg/ml; antidote and opioid antagonist for emergency reversal of opioid overdose.
• Gamma-OH (hydroxy-4 butyric acid) Hydroxy-4 butyric acid 200mg/ml solution for injection (IV); general anesthetic agent.
• Xenazine (tetrabenazine) Tetrabenazine 25mg scored tablets; treatment for movement disorders including chorea associated with Huntington's disease.
• Mysoline (primidone) Primidone 50mg or 250mg; antiepileptic for seizure management.
• Collatamp G Collagen 2.8 mg/cm2 with gentamicin sulfate 2.0 mg/cm2 implant; collagen haemostatic agent with antimicrobial properties for surgical use.
• Custodiol (HTK solution) Solution HTK for organ and tissue procurement; medical device for organ preservation during transplant procedures.
• Toxogonin (obidoxime chloride) Obidoxime chloride 250mg; cholinesterase reactivator for organophosphate poisoning treatment. Acquired from Merck in 2017.
• B.A.L. (dimercaprol) Dimercaprol 200mg with Butacaine 1mg solution for I.M. injection; heavy metal chelator for arsenic, mercury, and gold poisoning.
• L-Thyroxine SERB Levothyroxine sodium 200µg/ml solution for injection/infusion; thyroid hormone replacement therapy.
• Idefirix (imlifidase) Imlifidase; a treatment for desensitisation of highly sensitised adult patients prior to kidney transplantation from deceased donors. Conditionally approved in EU, Norway, Liechtenstein, Iceland, and UK.

Quantifiable outcome

• 90% one-year graft failure-free survival rate in highly sensitised kidney transplant patients treated with Idefirix (imlifidase) in post-authorisation study of 51 patients across 22 centres in 11 EU and UK countries
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Hansa Biopharma ABcoreOEM/ Whitelabel/ Licensing Partner · 19 May 2026Exclusive licensing agreement granting SERB development and commercialisation rights to Idefirix (imlifidase) for highly sensitised kidney transplant patients across EU, UK, Switzerland, Norway, Liechtenstein, Iceland, and MENA. Hansa receives €110M upfront plus €5M upon EMA filing acceptance. SERB assumes responsibility for PAES follow-up and paediatric study upon becoming MAH.
• Rothschild & Co. (financial advisor) and Freshfields (legal counsel)minorImplementation/ SI/ Consulting Partner · 19 May 2026Rothschild & Co. acted as exclusive financial advisor and Freshfields as legal counsel to SERB for the Idefirix licensing agreement. Centerview Partners UK LLP and Morgan Lewis served equivalent roles for Hansa Biopharma.
• Y-mAbs TherapeuticscoreStrategic or Co-development Partner · 16 September 2025SERB completed acquisition of Y-mAbs Therapeutics, a commercial-stage biopharma focused on antibody-based cancer therapeutics, for approximately $412M (all-cash, $8.60/share, ~105% premium). Y-mAbs became a wholly owned subsidiary of SERB and was delisted from Nasdaq. Key asset Danyelza (naxitamab-gqgk) strengthens SERB's rare oncology portfolio.
• CiVi BiopharmaminorOEM/ Whitelabel/ Licensing Partner · 21 October 2024SERB acquired Aurlumyn (iloprost IV), the only FDA-approved treatment for severe frostbite in the US, from CiVi Biopharma. Aurlumyn received priority review and orphan drug designation, approved February 2024. SERB planned to make it available for the winter season following acquisition.
• Emergent BioSolutions Inc.minorOEM/ Whitelabel/ Licensing Partner · 31 July 2024SERB acquired RSDL (Reactive Skin Decontamination Lotion) kit for approximately $75M upfront plus $5M milestone, including the leased manufacturing facility in Hattiesburg, Mississippi. RSDL is the only FDA-cleared device to remove/neutralise chemical warfare agents from skin, with 20 years of clinical data and 15M+ packets sold in 30+ countries.
• Rothschild & Co. (financial advisor) and Freshfields (legal counsel)minorImplementation/ SI/ Consulting Partner · 31 July 2024Rothschild & Co acted as exclusive financial advisor and Freshfields as legal counsel to SERB for the RSDL acquisition.
• Wellstat TherapeuticsminorOEM/ Whitelabel/ Licensing Partner · 13 July 2023SERB acquired Vistogard (uridine triacetate) for 5-FU/capecitabine overdose and Xuriden (uridine triacetate) for hereditary orotic aciduria from Wellstat Therapeutics. Products are commercially available in the US and distributed in Europe on named patient/compassionate use basis. SERB's BTG Pharmaceuticals entity sells products in the US.
• IpsenminorOEM/ Whitelabel/ Licensing Partner · 4 April 2022SERB acquired rights from Ipsen to commercialise Xermelo (telotristat ethyl) for carcinoid syndrome diarrhoea outside the US and Japan. Countries with market authorisation include Europe, Switzerland, Great Britain, Canada, Israel, Australia, Saudi Arabia, Mexico, and Russia.
• EMA/CHMP (European Regulatory)minorOthers · 14 January 2022European Medicines Agency Committee for Human Medicinal Products issued positive opinion leading to EU marketing authorisation for Voraxaze (glucarpidase) for high-dose methotrexate toxicity. Approved in all EU member states plus Iceland, Liechtenstein, and Norway.
• BTG Specialty Pharmaceuticals (acquired from Boston Scientific)coreStrategic or Co-development Partner · 1 March 2021SERB acquired BTG Specialty Pharmaceuticals (division of Boston Scientific) for an undisclosed amount, creating a global leader in critical care medicines. BTG brought US commercial presence, bio-manufacturing facilities in Wales, Australia, and Utah, and products including CroFab, Voraxaze, and DigiFab. The combined company had around 400 employees in 11 offices with direct presence across all major pharmaceutical markets.
• Veriton PharmaminorStrategic or Co-development Partner · 20 May 2020SERB acquired Veriton Pharma, a private pharmaceutical company specialising in licensed and unlicensed medicines for patients with special requirements, headquartered in Weybridge, UK with offices in Middle East and Australia. Portfolio of 60+ specialised formulations supplying 25+ countries. Added direct commercial presence in UK, Middle East, and Australia.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Alexion (AstraZeneca Rare Disease): Rare disease specialist within AstraZeneca, focused on complement-mediated and rare neurological/oncology indications. Comparable rare-disease positioning and US/EU commercial footprint.
• Hikma Pharmaceuticals: Global specialty pharmaceutical company with branded and generic injectables, including hospital specialty products. Comparable in supplying critical-care injectables (antidotes, anaesthesia, hospital specialty) across multiple geographies.
• Ipsen: European specialty pharma in oncology, rare disease, and neuroscience. Previously owned Xermelo (now licensed to SERB); comparable product portfolio focus on specialty/rare indications and European commercial model.
• Jazz Pharmaceuticals: Global specialty pharma focused on neuroscience and oncology, with several orphan/rare disease assets. Comparable commercial focus on specialty care, orphan drugs, and acquisition-driven growth.
• Vifor Pharma (CSL Vifor): Specialty pharma focused on iron deficiency, nephrology, and rare diseases. Comparable European specialty/rare disease commercial platform and overlap in transplant/nephrology patient segments with SERB's Idefirix.
• Recordati: European specialty pharma with a dedicated rare disease business (Orphan Europe) and broad specialty care portfolio. Comparable mix of rare disease and specialty care products with European and US commercial presence.

Direct peers

• Swedish Orphan Biovitrum (Sobi): European specialty pharmaceutical company focused on rare diseases across immunology, haematology, and specialty care. Comparable in business model — rare-disease franchise, European heritage, strong specialty commercial platform.
• Hansa Biopharma: Swedish biopharma developing imlifidase (Idefirix) for kidney transplantation and rare immunology indications. Direct transaction counterparty to SERB (May 2026, €115M licensing deal) and a direct comparator in the transplant desensitisation space.
• Emergent BioSolutions: US-based specialty pharma focused on CBRN medical countermeasures and antidotes. Directly comparable to SERB as the prior owner of RSDL (acquired by SERB in 2024) and a leading supplier to government stockpiling programs.

Emerging players

• Pacira BioSciences: Specialty pharma focused on non-opioid pain management and hospital-based therapeutics. Comparable in focusing on hospital-administered specialty products with limited competition and strong pricing power, though in different therapeutic categories.

Market position

Strengths5 records

Weaknesses6 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/serb_pharma
• LinkedInlinkedin.com/company/serb-pharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SERB Pharmaceuticals